Objective. The aim was to study the pathological role of lymphocytes with a peripheral T helper-cell-
CXCR5
À CD4 þ T cells were significantly elevated in IgG4-RD patients. Although no obvious change was observed in the percentage of total CD4 þ T cells, the percentage and absolute number of PD-1 þ
À CD4 þ T cells decreased in accordance with a reduction of serum IgG4 level after treatment with glucocorticoids.
Introduction
IgG4-related disease (IgG4-RD) is characterized by a high level of serum IgG4 and by chronic inflammation accompanied by storiform-type fibrosis mainly occurring in various non-lymphoid tissues [1] . The affected organs include the salivary and lacrimal glands, pancreas, lung and retroperitoneum, and organ involvement results in dysfunctions such as dacryoadenitis and sialadenitis (IgG4-DS, also so-called Mikulicz's disease) or type 1 autoimmune pancreatitis. Although the aetiology of IgG4-RD remains controversial, it is well recognized that the lesions of IgG4-RD preferentially harbour mature lymphocytes and IgG4-producing plasma cells, suggesting a certain immunological anomaly to drive the generation of IgG4 as the underlying mechanism of IgG4-RD. Recent studies on tissue-resident T follicular helper cells (Tfh cells, PD-1 hi CXCR5 þ CD4 þ T cells) and circulating 
Methods

Study populations
The characteristics of patients with IgG4-RD (n ¼ 53), patients with SS (n ¼ 16) and healthy volunteers (n ¼ 34) are summarized in supplementary Table S1 , available at Rheumatology Advances in Practice online. Patients in the IgG4-RD and SS groups and subjects in the healthy volunteer group were matched in terms of age. The organs involved in patients with IgG4-RD are summarized in supplementary Table S2 , available at Rheumatology Advances in Practice online. Diagnosis of IgG4-RD and SS was performed according to the 2011 comprehensive IgG4-RD diagnostic criteria [7] and the revised European criteria [8] , respectively. Treatment for IgG4-RD was performed according to the protocol previously described [9] . At the time of initial sampling of peripheral blood, none of the patients had received glucocorticoid therapy. Before entry to the treatment protocols, blood specimens were collected from the subjects and analysed. None of the healthy volunteers had abnormal physical or chest X-ray findings, and the results of all blood tests for the healthy volunteers were negative. Written informed consent was obtained in all cases according to the Declaration of Helsinki. All protocols were approved by the institutional review boards of Sapporo Medical University Hospital.
Antibodies
The following anti-human mAbs and isotype-matched control IgG were purchased from BD Biosciences (San Jose, CA, USA): mouse anti-CD3-APC (UCHT1), anti-CD4-APCCy7 (RPA-T4) and anti-PD-1-PE (EH12.1) mAbs, and a rat anti-CXCR5-PerCP-Cy5.5 (RF8B2) mAb. A recombinant anti-GZMA-PE (REA162) mAb was obtained from Miltenyi Biotec (Bergisch Gladbach, Germany).
Flow cytometry and cell sorting
Peripheral blood mononuclear cells were isolated from heparinized blood samples by centrifugation over a discontinuous density gradient (Lympholyte-H, Cedarlane, Burlington, ON, Canada). Cell staining using cell surface markers was performed as previously described [2] . Intracellular staining for GZMA was performed with the Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher Scientific, Waltham, MA, USA) as described in the manufacturer's protocol. Samples were then analysed and sorted using a FACSCanto II and FACSAria II, respectively (BD Biosciences). In each experiment using FACS-sorted cells, the purity of cells reached 95% after validation with reanalysis using FACSCanto II. All data were analysed using FACSDiva software (BD Biosciences) and FlowJo software (TreeStar, Ashland, OR, USA).
Quantitative real-time PCR
Quantitative real-time PCR was performed using a TaqMan Gene Expression Assay kit (Life Technologies, Carlsbad, CA, USA) with the Roche LightCycler 480 Real-Time PCR Detection System (Roche Diagnostics GmbH, Mannheim, Germany) as described in the manufacturer's protocol. For TaqMan-based detection, the amount of GAPDH mRNA was used to standardize the amounts of target transcripts, including IL4 (Hs00174122) and IL21 (Hs00222327). The DDCT method was used to calculate the relative levels of transcripts in triplicate specimens.
Statistical analysis
All data are shown as medians. Significant differences between any two groups were determined by using the Mann-Whitney U test. Multiple group comparisons were analysed with the Kruskal-Wallis test. Correlations were determined by Spearman's correlation coefficient, and probability values <0.05 were considered statistically significant. Fig. 2A and  supplementary Fig. S2 , available at Rheumatology Advances in Practice online. In accordance with the results as shown in Fig. 1D and E, the number of organs involved (r ¼ 0.5638, P < 0.0001) and the serum level of soluble IL-2 receptor (r ¼ 0.4780, P < 0.001) were positively associated with the percentage of PD-
Results
PD
We next addressed the question of whether standard treatment with glucocorticoids affected the proportion of circulating PD-1 þ CXCR5 À CD4 þ T cells, because glucocorticoids have been shown to be fairly effective for improving clinical manifestations of patients with IgG4-RD [9, 11] . Of note, after glucocorticoid treatment, the percentage and absolute number of PD-
cells were markedly decreased in parallel with the reduction of serum IgG4 level ( Fig. 2B and C) . In contrast to these remarkable changes of PD-
cells, the treatment itself did not seem to influence the percentage of total CD4 þ T cells in patients with IgG4-RD (Fig. 2B) . Finally, we would like to address the functional prop- 
Discussion
In the present study, we comprehensively investigated peripheral blood leucocytes from patients with IgG4-RD and, for the first time, showed the clinical relevance of circulating PD-1 þ CXCR5 À CD4 þ T cells (termed Tph-like cells here), which are increased in this disease. PD-1 has been postulated as a common activation molecule for naïve and memory phenotypes of CD4 þ T cells in peripheral blood and lymphoid tissues and even in synovia from patients with RA [14, 15] . Thus, Tph-like cells in IgG4-RD would include recently activated and/or memory CD4 þ T cells. The precise mechanism by which Tph-like cells in IgG4-RD are activated and then maintained is still unclear, although it has been suggested that B cells, which are abundantly localized in the lesions of IgG4-RD, might act as antigen-presenting cells that are probably related to the pathogenesis of IgG4-RD [16] . As shown in supplementary Fig. S5 , available at Rheumatology Advances in Practice online, significant correlations were found between circulating PD- 
cells (Tfh cells) and PD-
þ cells from IgG4-RD patients with or without multiple involvement of other organs (Comorbidities) in addition to lacrimal and/or salivary glands are shown. *P < 0.05, **P < 0.01, ****P < 0.0001; ns: not significant. IgG4-RD: IgG4-related disease. Given that CXCR5 is preferentially expressed on Tfh cells and B cells and that CXCL13, the ligand of CXCR5, is produced by follicular dendritic cells and by high endothelial venule cells in lymphoid follicles, the pathological background associated with humoral immune responses in IgG4-RD has been focused on and analysed [16] . In light of this anatomical distribution of CXCR5 and CXCL13, attention should be paid to 
CD4
þ T cells in healthy volunteers (Healthy) and in patients with IgG4-RD are shown. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns: not significant. GZMA: granzyme A; IgG4-RD: IgG4-related disease; sIL-2R: soluble IL-2 receptor. the fact that the level of circulating Tfh cells (PD-1 [5] . Given that fractalkine, which is a ligand of CX3CR1, is expressed by activated endothelial cells within inflamed tissues, Tph cells might have a potential role in the initiation of inflammation and maintenance of the chronic fibroinflammation of IgG4-RD by influencing vascularity [18] . Destructive inflammation is observed in IgG4-RD, and our experimental evidence indicates that Tph-like cells that preferentially contained a cytotoxic granule of GZMA are responsible for these pathological changes in IgG4-RD. In the present study, we could not see abundant expression of IL4 and IL21 mRNAs in Tph-like cells compared with that in Tfh cells from patients with IgG4-RD (supplementary Fig. S4 , available at Rheumatology Advances in Practice online). Taken together, Tph-like cells in IgG4-RD would play a pathological role as CD4 þ cytotoxic T cells rather than as B cell helpers, such as Tfh cells.
In conclusion, circulating Tph-like cells seem to have pathological importance in IgG4-RD. Diagnosis of IgG4-RD remains difficult owing to its extensive spectrum of clinical manifestations. Moreover, cellular and molecular parameters, such as IgG4 þ plasma cells in affected tissues and serum IgG4 level, are neither sensitive nor specific for the diagnosis of IgG4-RD. Thus, the increased level of Tph-like cells in patients with IgG4-RD could support the diagnosis and monitoring of the efficacy of standard glucocorticoid therapy.
